Matrix metalloproteinase 1 (MMP-1) is necessary for degradation of interstitial collagen types I, II, and III, which are the major constituents of the extracellular matrix (ECM). Increased expression of MMP-1 has been correlated with invasiveness of certain malignancies and cartilage degradation in rheumatoid arthritis. Increased transcriptional activity of MMP-1 has been reported with a single nucleotide polymorphism (SNP) of the MMP-1 promoter. Systemic sclerosis (SSc) is characterized by increased accumulation and turnover of collagen and other components of ECM. Previous studies have reported increased expression of MMP-1 transcripts in SSc fibroblasts. Therefore, we sought to determine if SSc patients with early disease (р5 years) from a multi-ethnic cohort were more or less likely than ethnically-matched normal controls to have an increased frequency of the high promoter activity MMP-1 genotype and whether MMP-1 promoter genotypes correlated with any of the major clinical manifestations of
The increased accumulation and turnover of collagen and other extracellular matrix (ECM) components are important molecular processes that contribute to the cutaneous and visceral fibrosis seen in scleroderma or systemic sclerosis (SSc). 1, 2 Matrix metalloproteinases are a family of enzymes that are essential in the remodeling of the ECM both in normal and pathologic states. 3 Matrix metalloproteinase 1 (MMP-1) is the only enzyme able to initiate degradation of interstitial collagen types I, II, and III which are major constitutes of the ECM. Increased expression of MMP-1 has been correlated with an invasive phenotype of human melanoma, 4 as well as cartilage destruction in rheumatoid arthritis. 5 Previously, studies of fibroblasts from patients with early SSc (disease duration р1 year) reported increased mRNA levels of MMP-1, MMP-3, and TIMP-1, compared to controls. 6 Consistent with this are our own cDNA microarray studies of dermal fibroblasts where increased levels of MMP-1 transcripts were found in SSc fibroblasts compared to control fibroblasts, 7 implying transcriptional activation of the MMP-1 gene in SSc fibroblasts.
Recently, a single nucleotide polymorphism (SNP) in the MMP-1 promoter resulting from a guanine insertion at −1607 bp (ie, the GGA vs GA genotype) was reported to cause a two to ten-fold increase in transcriptional activity of MMP-1. 8 Brinckerhoff et al 8 further suggest that an increased GGA gentotype enhances the invasive behavior of tumor cells as a consequence of the increased transcripition of MMP-1. Since SSc fibroblasts appear to have increased MMP-1 transcriptional activity, the purpose of this study was to ascertain whether frequencies of this functionally relevant MMP-1 promoter SNP were increased in SSc patients, and whether MMP-1 genotypes correlated with any of the major clinical manifestations of SSc.
A multi-ethnic cohort of SSc patients from a large prospective outcome study (Genetics versus ENvironment In Scleroderma Outcome Study or GENISOS) 9 and ethnically-matched controls were genotyped for the MMP-1 promoter. All patients met the proposed American Col- Mantel-Haenszel P-value = 0 .060 (overall)* Mantel-Haenszel P-value = 0.024 (GA/GA vs others)**, OR = 2.604, 95% CI = (1.103, 6.144) *+/− the presence of any significant differences among the three genotypes. ** +/− the presence of any significant differences between the GA/GA genotype vs (GA/GGA and GGA/GGA) genotypes. a Includes pulmonary hypertension (by echocardiography or right heart catheterization), pulmonary fibrosis (by high resolution CT or biopsy), or pneumonitis.
b
Includes pericarditis/pericardial effusion, arrythmias, congestive heart failure, cardiomyopathy, or pulmonic heart sound Ͼ aortic heart sound (P 2 Ͼ A 2 ). c Includes serum creatinine Ͼ1.5 mg/dl, proteinuria Ͼ500 mg/24 hours, end-stage renal disease, or scleroderma renal crisis (sudden onset of accelerated hypertension, rapidly progressive renal insufficiency, and microangiopathic hemolysis). Includes esophageal dysmotility (by barium swallow or manometry), dysphagia, gastroesophageal reflux, pseudo-obstruction (radiographic diagnosis), or malabsorption.
e Includes arthritis (not attributed to osteoarthritis, gout, or trauma), myositis (proximal muscle weakness with one of the following: elevated creatine kinase, myopathic changes on electromyography, and/or a characteristic muscle biopsy), tendon friction rubs, or joint contractures.
lege of Rheumatology (ACR) criteria for SSc 10 and had disease duration р5 years at study entry. Extensive clinical and serologic data had been collected previously on each patient. 9 Clinical information in this study included all cutaneous manifestations of SSc (including limited vs diffuse scleroderma classifications according to the criteria of LeRoy et al 11 and the modified Rodnan skin score 12 ) and major end-organ involvement such as gastrointestinal, cardiac, pulmonary, renal, and musculoskeletal disease (see Table 1 ). Autoantibodies to centromere were determined by indirect immunofluorescence of HEp-2 cells (Antibodies Inc, Davis, CA, USA); topoisomerase I, Sm, RNP, Ro, and La by immunodiffusion (Inova Diag- 6 the forward primer labeled with 6-FAM and reverse primer tailed (Applied Biosystems). PCR products were analyzed on an ABI Prism 310 Genetic Analyzer with Genescan  /Genotyper  software. Individual electropherograms were examined manually to assure correct genotype interpretation. Chi-square and Fisher's exact tests were used to assess any differences in MMP-1 promoter allele frequencies between SSc cases and ethnically-matched controls, and to test for significant association with the major disease manifestations or SSc autoantibodies.
nostics, San Diego, CA, USA); and those to U3-RNP (fibrillarin) by immunoprecipitation. 13 The results show that the frequencies of the MMP-1 promoter SNP (ie, the GA/GA, GA/GGA, GGA/GGA genotypes) were not significantly different between SSc patients and the ethnically-matched controls in all three ethnic groups studied (Table 2) . Moreover, the frequencies of the MMP-1 genotypes were quite similar among controls in the three ethnic groups (Table 2 ). There also was no significant difference when the SSc patients were stratified by diffuse vs limited SSc ( 2 = 0.2469, P = 0.884), and the skin scores at the time of enrollment were not significantly different among patients of the three MMP-1 promoter genotypes (P = 0.704). There was no association with the presence of SSc autoantibodies (anti-topoisomerase I, centromere, fibrillarin, Sm, RNP, Ro, La) studied at the time of enrollment. Finally, there was no significant association among the different MMP-1 promoter genotypes with any major disease manifestations or end-organ involvement even when ethnicity was taken into account, except for a weak association with musculoskeletal manifestations (see Table 1 ) and the GA homozygous state. This association lost statistical significance when adjusted for multiple comparisons (for five comparisons, ␣ = 0.01).
Previous reports show that MMP-1 transcripts are upregulated in SSc fibroblasts, however, this study failed to demonstrate any genetic association with SSc with the high activity MMP-1 promoter genotype. The data imply that the promoter SNP alone cannot account for the increased MMP-1 transcripts found in SSc fibroblasts, and that secondary factors, such as post-transcriptional events, cytokines (such as TGF-␤ 14 and IL-1␤ 15 ), or other epistatic effects may be more important. A search of the recently released working draft of the human genome revealed 35 SNPs for MMP-1 (accession no. NTF009151), five of which are coding SNPs. Thus although this polymorphism is the only known genetic variation of MMP-1 that has functional significance, it is possible that these other genetic variations in MMP-1 may ultimately prove to be of functional significance. Finally, it should be noted that the prospective SSc cohort in this report had early disease, and it remains to be determined if this SNP correlates with SSc outcome (such as worsening skin scores) over time.
